MARILYN BROOKS: Open Payments
NPI 1366641821 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$435 in 12 payments from 7 companies in 2025. Trend: 2023 $152 · 2024 $456 · 2025 $435
Food & beverage: $435
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $175 |
| Otsuka America Pharmaceutical, Inc. | 2 | $143 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Viatris Specialty LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
Products named: REXULTI, Ozempic, Wegovy, TRELEGY ELLIPTA, YUPELRI, MOUNJARO, PROQUAD, ZORYVE.
Industry payments across CA — which companies pay providers there.
